BiotechTube
Home/Pipeline/QPOR Platform for Breast Cancer

QPOR Platform for Breast Cancer

Breast Cancer

Breakthrough Device DesignationActive

Key Facts

Indication
Breast Cancer
Phase
Breakthrough Device Designation
Status
Active
Company
4D Path

About 4D Path

4D Path is a private, pre-revenue diagnostics company founded in 2017 and headquartered in Cambridge, Massachusetts. The company has developed the QPOR™ Platform, a proprietary AI/ML platform that extracts novel biological signatures from standard pathology slides to predict therapeutic response across multiple cancer types and drug classes. With FDA Breakthrough Device Designation for breast cancer diagnostics and validation studies with leading cancer centers, 4D Path is positioning its technology as a tool for both clinical decision support and biopharma drug development partnerships.

View full company profile

Therapeutic Areas

Oncology

Other Breast Cancer Drugs

DrugCompanyPhase
Antifibrotic Therapy ProgramMeCo DiagnosticsPre-clinical
inPROBE for HER2SDS OpticClinical Investigation
ACT‑BC1AnthrocellPreclinical
APA-1000 Breast Thermotherapy SystemMedifocusPhase III
Early‑Detection Breast Cancer ScreeningKarkinos HealthcareMarket
Unnamed Breast Cancer ProgramClick TherapeuticsPilot/Phase 2
Lerociclib (Lerocliclib)Chemogenics BioPharmaPhase 3
AT-017Asieris PharmaceuticalsNot Specified
CDK2 inhibitorAcelleraPre-clinical
NP-G2-044Novita PharmaceuticalsPhase 2a
Maveropepimut-S (MVP-S)BioVaxysClinical Evaluation
Cannabics® BRST-33CNBX PharmaceuticalsDiscovery